Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ability to comply with the study protocol
Chronic AD that has been present for at least 3 years before the screening visit
Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications (medications or treatments applied directly to part of the body) or for whom topical treatments are otherwise medically inadvisable
You may not be if
Prior treatment with MSTT1041A
Treatment with any investigational therapy (with the exception of biologics) within 8 weeks or within 5 half-lives whichever is longer, before screening
Treatment with any cell-depleting agents within 6 months before screening, or until lymphocyte count returns to normal, whichever is longer
Treatment with other biologics within 3 months or 5 half-lives before screening, whichever is longer
Comorbid conditions that may interfere with evaluation of investigational medicinal product
History or evidence of substance abuse that would pose a risk to participant safety, interfere with the conduct of the study, have an impact on the study results, or affect the participant's ability to participate in the study
History of anaphylaxis, hypersensitivity to a biologic agent, or known hypersensitivity to any component of the MSTT1041A or placebo injection
Planned surgical intervention during the course of the study
Pregnant or breastfeeding, or intending to become pregnant during the study
Participant who is a member of the investigational team or his/her immediate family
Clareo Health | A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
